•  
  •  
  •  
  •  

2026-05-24 01:01:37

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores

Keywords Selected:  Capsules

Stock Report

  • Natural Biogenex and Fermbox Bio Enter Strategic Framework and Manufacturing Agreements to Strengthen Fermentation-Based CDMO Capabilities
  • NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst&®) in the U.S. market
  • Department of Drug Controller directs Natural Capsules Ltd to close operations of plant
  • Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
  • Zydus receives final approval from USFDA for Enzalutamide Capsules, 40 mg
  • Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg
  • Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Doxycycline Capsules, 40 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg
  • Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg - OTC
  • Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S.
  • Granules India Limited announced ANDA Approval for Colchicine Capsules
  • Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States
  • Aurobindo Pharma receives USFDA Approval for Fingolimod Capsules, 0.5 mg
  • Strides receives USFDA approval for Pregabalin Capsules
  • Zydus receives Final Approvals from the USFDA for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg
  • Zydus receives final approval from the USFDA for Cyclophosphamide Capsules USP, 25 mg and 50 mg
  • Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal
  • Strides receives USFDA approval for Icosapent Ethyl Capsules
  • Marksans Pharma Ltd announces US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg
  • Strides receives USFDA approval for Icosapent Ethyl Capsules
  • Natural Biogenex Pvt Ltd performs inauguration at Tumkur unit
  • Zydus receives final approval from the USFDA for Isotretinoin Capsules USP, 10 mg, 20 mg 30 mg and 40 mg
  • Ajanta Pharma Ltd receives final approval from US FDA for Topiramate Extended Release Capsules

Latest Post

  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025